Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (1-10 of 181) with videos related to

Pageof 19
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
The use of obinutuzumab in chronic lymphocytic leukemiaWilliam Wierda
Clinical Advances in Hematology & Oncology : H&O|March 11, 2009
New prognostic factors in chronic lymphocytic leukemiaWilliam Wierda
Cancers|February 13, 2025
Improving Treatment Options for Patients with Double Refractory CLLRyan Jacobs, William Wierda
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentationRussell Gollard, William Wierda, Jonathan Trent
The New England Journal of Medicine|August 22, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLL. ReplyNitin Jain, Varsha Gandhi, William Wierda
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Investigational immunotherapeutics for B-cell malignanciesAlfonso Quintás-Cardama, William Wierda, Susan O'Brien
Current Hematologic Malignancy Reports|April 29, 2010
New aspects of the treatment of chronic lymphocytic leukemiaStefan Faderl, William Wierda, Michael J Keating
Hemasphere|February 26, 2026
Is CLL curable?Nitin Jain, Alessandra Ferrajoli, Susan O'Brien, et al.
Leukemia & Lymphoma|August 8, 2012
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cellsKumudha Balakrishnan, Sumesh Aggarwal, William Wierda, et al.
Journal of Blood Medicine|January 28, 2012
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)Aref Al-Kali, William Wierda, Michael Keating, et al.
Pageof 19

Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
The use of obinutuzumab in chronic lymphocytic leukemiaWilliam Wierda
Clinical Advances in Hematology & Oncology : H&O|March 11, 2009
New prognostic factors in chronic lymphocytic leukemiaWilliam Wierda
Cancers|February 13, 2025
Improving Treatment Options for Patients with Double Refractory CLLRyan Jacobs, William Wierda
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentationRussell Gollard, William Wierda, Jonathan Trent
The New England Journal of Medicine|August 22, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLL. ReplyNitin Jain, Varsha Gandhi, William Wierda
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Investigational immunotherapeutics for B-cell malignanciesAlfonso Quintás-Cardama, William Wierda, Susan O'Brien
Current Hematologic Malignancy Reports|April 29, 2010
New aspects of the treatment of chronic lymphocytic leukemiaStefan Faderl, William Wierda, Michael J Keating
Hemasphere|February 26, 2026
Is CLL curable?Nitin Jain, Alessandra Ferrajoli, Susan O'Brien, et al.
Leukemia & Lymphoma|August 8, 2012
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cellsKumudha Balakrishnan, Sumesh Aggarwal, William Wierda, et al.
Journal of Blood Medicine|January 28, 2012
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)Aref Al-Kali, William Wierda, Michael Keating, et al.
Pageof 19